Clinical and environmental aspects of amyotrophic lateral sclerosis in moroccan population: a study of 60 cases

##plugins.themes.academic_pro.article.sidebar##

Published Oct 27, 2015
Download
pdf
Vol. 93 No. 6 (2015): Issue Jun 2015

##plugins.themes.academic_pro.article.main##

Fatima Imounan
Siham Lahbouje
Yahya Hsaini
Wafa Regragui
El Hachmia Ait Ben Haddou
Ali Benomar
Ahmed Bourazza
Mohamed Yahyaoui

Abstract

Background: Amyotrophic lateral sclerosis (ALS) is the most common disease of the motor neuron disease. Its etiology remains unknown but several studies incriminate the environmental factors in its genesis.
The aim: of this study was to describe the epidemiological, clinical and environmental aspects of ALS in Moroccan population.
Methods: 60 ALS patients were recruited over a period of 5 years from January 2008 to September 2012. Patients were evaluated by detailed record of exploitation. Statistical analysis was performed using SPSS 13.0.
Results: The average age of the population was 52.1 ± 11.2 years with a sex ratio of M/F = 1.5. The average age of onset was 50 ± 11.7 years. In the group of patients exposed to toxic a significantly higher proportion of solvent exposure was found (p = 0.02). However there was no significant association with exposure to heavy metals, pesticides, or with toxic and eating habits. ALS is more frequent in the west region of Morocco (p = 0.03).
Conclusions: The positive association between exposure to solvents and ALS found in our population has been reported in the literature. The frequency of the ALS early west region suggests may be environmental or genetic origin. These results are preliminary and require a multicenter study to have more data and better highlight the environmental characteristics of ALS in the Moroccan population.

Keywords:

Environmental factors; Amyotrophic lateral sclerosis; Pathogenesis

##plugins.themes.academic_pro.article.details##

References

  1. Soriani MH, Desnuelle C. Epidémiologie de la SLA. Revue neurologique 2009; 165: 627-640.
  2. Brooks BR, EL ESCORIAL World Federation of Neurology criteria for he diagnosis of amyotrophic lateral sclerosis. Subcommitee on motor Neuron Diseases/Amyotrophic lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El scorial ‘‘Clinical limits of amyotrophic lateral sclerosis rkshop contributors. J Neurol Sci 1994; 124: 96-107.
  3. Morahan JM, Pamphlett R. Amyotrophic lateral sclerosis and exposure to environmental toxins: an Australian casecontrol study. Neuroepidemiology 2006; 27: 130-5.
  4. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis.J Neurol 1985; 232: 295-300
  5. Bouche P, Le Forestier N. Sclérose latérale amyotrophique Aspects cliniques. EMC neurologie 1999 ; 17-078-A-10.
  6. Lawyer T, Netsky MG. Amyotrophic lateral sclerosis. A clinico-anatomic study of fifty-three cases. Arch Neurol 1953; 69: 171-192
  7. Harvey DG, Torack RM, Rosenbaum HE. Amyotrophic lateral sclerosis wit opthalmoplegia. A clinicopathologic study. Arch Neurol 1979; 36: 615- 617.
  8. Cox PA, Banack S, Murch S, Sacks O. Commentary on: Return of the cycad hypothesis-does the amyotrophic lateral sclerosis/Parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health. Neuropathol Appl Neurobiol 2006; 32: 679-82.
  9. Cronin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007; 68: 1002-7.
  10. Chancellor AM, Slattery JM, Fraser H, Warlow CP. Risk factors for motor neuron disease: a case-control study based on patients from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1993; 56: 1200-6.
  11. Chio A, Meineri P, Tribolo A, Schiffer D. Risk factors in motor neuron disease: a case-control study. Neuroepidemiology 1991; 10: 174-84
  12. Gunnarsson LG, Bodin L, Soderfeldt B, Axelson O. A case-control study of motor neuron disease: its relation to heritability, and occupational exposures, particularly to solvents. Br J Ind Med 1992; 49: 791-8.
  13. Mcguire V, Longstreth JR WT, Nelson LM, et al. Occupational exposures and amyotrophic lateral sclerosis. A population-based casecontrol study. Am J Epidemiol 1997; 145: 1076- 88.
  14. Deapen DM, Henderson BE. A case-control study of amyotrophic lateral sclerosis. Am J Epidemiol 1986; 123: 790-9.
  15. Granieri E, Carreras M, Tola R, et al. Motor neuron disease in the province of Ferrara, Italy, in 1964-1982. Neurology 1988; 38: 1604-8.
  16. Savettieri G, Salemi G, Arcara A, Cassata M, Castiglione MG, Fierro B. A case-control study of amyotrophic lateral sclerosis. Neuroepidemiology 1991; 10: 242-5.
  17. Qureshi MM, Hayden D, Urbinelli L, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2006; 7: 173-82.
  18. Qureshi MM, Hayden D, Urbinelli L, et al. Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2006; 7: 173-82.
  19. Armon C, Kurland LT, Daube JR, O'brien PC. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology 1991; 41: 1077-84.
  20. Vinceti M, Guidetti D, Bergomi M, et al. Lead, cadmium, and selenium in the blood of patients with sporadic amyotrophic lateral sclerosis. Ital J Neurol Sci 1997; 18: 87-92.
  21. Kapaki E, Zournas C, Kanias G, Zambelis T, Kakami A, Papageargiou C. Essential trace element alterations in amyotrophic lateral sclerosis. J Neurol Sci 1997; 147: 171-175.
  22. Kasarskis EJ, Tandon L, Lovell MA, Ehmann WD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: a preliminary study. J Neurol Sci 1995; 130: 203-208.
  23. Bergomi M, Vinceti M, Nacci G, et al. Environmental exposure to trace elements and risk of amyotrophic lateral sclerosis: a population-based case-control study. Environ Res 2002; 89: 116-123.
  24. Nelson LM, Matkin C, Longstreth JR WT, Mcguire V. Populationbased case-control study of amyotrophic lateral sclerosis in western Washington State, IL. Diet Am J Epidemiol 2000; 151: 164-73.
  25. Morozova N, Weisskopf MG, Mccullough ML, et al. Diet and amyotrophic lateral sclerosis. Epidemiology 2008; 19: 324-37.
  26. Ascherio A, Weisskopf MG, O'reilly EJ, et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol 2005; 57: 104-10.
  27. Veldink JH, Kalmijn S, Groeneveld GJ, et al. Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2007; 78: 367-71.
  28. Fang F, Bellocco R, Hernan MA, Ye W. Smoking, snuff dipping and the risk of amyotrophic lateral sclerosis - a prospective cohort study. Neuroepidemiology 2006; 27: 217-21.
  29. Weisskopf MG, Mccullough ML, Calle EE, Thun MJ, Cudkowicz M, Ascherio A. Prospective study of cigarette smoking and amyotrophic lateral sclerosis. AmJ Epidemiol 2004; 160: 26-33.
  30. Kondo K, Tsubaki T. Case-control studies of motor neuron disease: association with mechanical injuries. Arch Neurol 1981; 38: 220-6
  31. Kamel F, Umbach DM, Munsat TL, Shefner JM, Sandler DP. Association of cigarette smoking with amyotrophic lateral sclerosis. Neuroepidemiology 1999; 18:194-202.
  32. Veldink JH, Kalmijn S, Groeneveld GJ, Titulaer MJ, Wokke JH, Van Den Berg LH. Physical activity and the association with sporadic ALS. Neurology 2005; 64: 241-5.